ORLANDO, Fla., Sept. 05, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE - - Immune Therapeutics, Inc. (OTCQB: IMUN), a late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS, today announced that the Company’s multi-pronged growth strategy, which includes the pursuit of the multi-billion dollar pet care industry, was favorably mentioned in an article published today in Forbes Magazine. (Link to Story: Can Cats and Dogs Help Reverse Marijuana’s Stigma?)
The article, which also includes excerpts from an interview with the Company’s CEO, Noreen Griffin, classifies Immune Therapeutics as a ‘pioneering biopharmaceutical company that recognized the massive potential in the growing animal health market and has introduced a partnership to tap into it’ (referring to the Company’s recent 10% acquisition of Cytocom, Inc. which included exclusive rights to Lodonal™ and Met-Enkephline for the treatment of pets in the United States).
“Today’s positive coverage of Immune Therapeutics by such a well-respected and internationally distributed publication, such as Forbes, is a yet another indication that Immune has truly embarked on a new era of growth and expansion as we look towards the bright future that lays ahead,” said Ms. Griffin. “We believe the ongoing progress we are making in Africa, along with the recent filings of new patents and the exclusive revenue channels stemming from the pet care industry will further strengthen Immune Therapeutics, Inc.’s market position,” concluded Ms. Griffin.
Immune Therapeutics Gains Exclusive Drug Rights for Booming Pet Care Industry
The global market for animal medication is projected to reach $44.4 billion by 2022, driven by increasing investments in animal drug development in response to unmet animal health needs and developments in veterinary diagnostics and services. Overall, 68% of U.S. households, or about 84.6 million homes, own a pet, according to the APPA. Dogs and cats are the most popular pets, followed by freshwater fish and birds.
ABOUT IMMUNE THERAPEUTICS, INC.
Immune Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of highly innovative immunotherapies. Immune Therapeutics is actively developing T-Activation immunotherapies to achieve immunomodulation in patients both human and pets with autoimmune and inflammatory disease, cancer and infectious diseases.
This release may contain forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to, the possibility that some or all the matters and transactions considered by the Company may not proceed as contemplated, and by all other matters specified in the Company’s filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company’s filings with the Securities and Exchange Commission (www.sec.gov), including its recent periodic reports.